Literature DB >> 21803722

Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function.

Janna Cohen-Lehman1, Marina M Charitou, Irwin Klein.   

Abstract

OBJECTIVE: To review the potential adverse effects of thyroid hormone-based nutraceuticals and describe a case of thyrotoxic periodic paralysis (TPP) after abuse of a dietary supplement containing 3,5,3'-triiodothyroacetic acid (tiratricol).
METHODS: We review the literature on potential dangers and therapeutic misadventures of thyroid hormone-based nutraceuticals and present the clinical, laboratory, and radiologic data of a bodybuilder in whom hypokalemic TPP developed after use of "Triax Metabolic Accelerator".
RESULTS: A 23-year-old white man developed lower extremity paralysis, diaphoresis, and palpitations in the setting of low serum potassium levels. Laboratory results showed suppressed thyroid-stimulating hormone, low levels of free and total thyroxine, low total triiodothyronine level, and very low 24-hour radioiodine uptake. The patient ultimately admitted to taking a supplement containing tiratricol for approximately 2 months, and hypokalemic TPP was diagnosed. He was treated with potassium supplementation and a β-adrenergic blocking agent, which completely resolved his symptoms. Results of thyroid function tests normalized or approached normal 1 week after hospitalization, and future use of dietary supplements was strongly discouraged. Despite 2 warnings by the US Food and Drug Administration, products containing tiratricol are still available for sale on the Internet.
CONCLUSION: This report illustrates both an unusual adverse effect of a nutraceutical containing tiratricol and the importance of educating our patients about the risks versus benefits of using these widely available but loosely regulated products.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803722     DOI: 10.4158/EP10137.RA

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  8 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 2.  Thyroid hormone misuse and abuse.

Authors:  Victor J Bernet
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  THYROTOXIC PERIODIC PARALYSIS IN A COMPETITIVE BODYBUILDER WITH THYROTOXICOSIS FACTITIA.

Authors:  Amy J Patel; Stephanie Tejera; Stanislaw P Klek; Gary D Rothberger
Journal:  AACE Clin Case Rep       Date:  2020-09-21

4.  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa.

Authors:  Seiya Kitamura; Kelli L Hvorecny; Jun Niu; Bruce D Hammock; Dean R Madden; Christophe Morisseau
Journal:  J Med Chem       Date:  2016-05-04       Impact factor: 7.446

Review 5.  Thyrotoxic periodic paralysis: clinical and molecular aspects.

Authors:  Henrik Falhammar; Marja Thorén; Jan Calissendorff
Journal:  Endocrine       Date:  2012-08-24       Impact factor: 3.633

Review 6.  Physiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

7.  Thyrotoxic periodic paralysis associated with transient thyrotoxicosis due to painless thyroiditis.

Authors:  Sang Bo Oh; Jinhee Ahn; Min Young Oh; Bo Gwang Choi; Ji Hyun Kang; Yun Kyung Jeon; Sang Soo Kim; Bo Hyun Kim; Yong Ki Kim; In Joo Kim
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

Review 8.  Thyrotoxic periodic paralysis: clinical challenges.

Authors:  Abhishek Vijayakumar; Giridhar Ashwath; Durganna Thimmappa
Journal:  J Thyroid Res       Date:  2014-02-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.